Source:http://linkedlifedata.com/resource/pubmed/id/12121233
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1
|
| pubmed:dateCreated |
2002-7-17
|
| pubmed:abstractText |
Neoplasms of histiocytes and dendritic cells are rare, and their phenotypic and biological definition is incomplete. Seeking to identify antigens detectable in paraffin-embedded sections that might allow a more complete, rational immunophenotypic classification of histiocytic/dendritic cell neoplasms, the International Lymphoma Study Group (ILSG) stained 61 tumours of suspected histiocytic/dendritic cell type with a panel of 15 antibodies including those reactive with histiocytes (CD68, lysozyme (LYS)), Langerhans cells (CD1a), follicular dendritic cells (FDC: CD21, CD35) and S100 protein. This analysis revealed that 57 cases (93%) fit into four major immunophenotypic groups (one histiocytic and three dendritic cell types) utilizing six markers: CD68, LYS, CD1a, S100, CD21, and CD35. The four (7%) unclassified cases were further classifiable into the above four groups using additional morphological and ultrastructural features. The four groups then included: (i) histiocytic sarcoma (n=18) with the following phenotype: CD68 (100%), LYS (94%), CD1a (0%), S100 (33%), CD21/35 (0%). The median age was 46 years. Presentation was predominantly extranodal (72%) with high mortality (58% dead of disease (DOD)). Three had systemic involvement consistent with 'malignant histiocytosis'; (ii) Langerhans cell tumour (LCT) (n=26) which expressed: CD68 (96%), LYS (42%), CD1a (100%), S100 (100%), CD21/35 (0%). There were two morphological variants: cytologically typical (n=17) designated LCT; and cytologically malignant (n=9) designated Langerhans cell sarcoma (LCS). The LCS were often not easily recognized morphologically as LC-derived, but were diagnosed based on CD1a staining. LCT and LCS differed in median age (33 versus 41 years), male:female ratio (3.7:1 versus 1:2), and death rate (31% versus 50% DOD). Four LCT patients had systemic involvement typical of Letterer-Siwe disease; (iii) follicular dendritic cell tumour/sarcoma (FDCT) (n=13) which expressed: CD68 (54%), LYS (8%), CD1a (0%), S100 (16%), FDC markers CD21/35 (100%), EMA (40%). These patients were adults (median age 65 years) with predominantly localized nodal disease (75%) and low mortality (9% DOD); (iv) interdigitating dendritic cell tumour/sarcoma (IDCT) (n=4) which expressed: CD68 (50%), LYS (25%), CD1a (0%), S100 (100%), CD21/35 (0%). The patients were adults (median 71 years) with localized nodal disease (75%) without mortality (0% DOD). In conclusion, definitive immunophenotypic classification of histiocytic and accessory cell neoplasms into four categories was possible in 93% of the cases using six antigens detected in paraffin-embedded sections. Exceptional cases (7%) were resolvable when added morphological and ultrastructural features were considered. We propose a classification combining immunophenotype and morphology with five categories, including Langerhans cell sarcoma. This simplified scheme is practical for everyday diagnostic use and should provide a framework for additional investigation of these unusual neoplasms.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jul
|
| pubmed:issn |
0309-0167
|
| pubmed:author |
pubmed-author:BanksPP,
pubmed-author:CampySS,
pubmed-author:ChanJ K CJK,
pubmed-author:De Wolf-PeetersCC,
pubmed-author:DelsolGG,
pubmed-author:FaliniBB,
pubmed-author:FaveraR DRD,
pubmed-author:GascoyneR DRD,
pubmed-author:GatterK CKC,
pubmed-author:GaulardPP,
pubmed-author:GroganT MTM,
pubmed-author:HarrisN LNL,
pubmed-author:HwaVV,
pubmed-author:IsaacsonP GPG,
pubmed-author:JaffeE SES,
pubmed-author:KluinPP,
pubmed-author:KnowlesD MDM,
pubmed-author:Müller-HermelinkH-KHK,
pubmed-author:MasonD YDY,
pubmed-author:MoriSS,
pubmed-author:PileriS ASA,
pubmed-author:PirisM AMA,
pubmed-author:RalfkiaerEE,
pubmed-author:SteinHH,
pubmed-author:WarnkeR ARA,
pubmed-author:WeissL MLM
|
| pubmed:issnType |
Print
|
| pubmed:volume |
41
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1-29
|
| pubmed:dateRevised |
2007-11-14
|
| pubmed:meshHeading |
pubmed-meshheading:12121233-Adult,
pubmed-meshheading:12121233-Aged,
pubmed-meshheading:12121233-Dendritic Cells,
pubmed-meshheading:12121233-Female,
pubmed-meshheading:12121233-Histiocytes,
pubmed-meshheading:12121233-Histiocytic Disorders, Malignant,
pubmed-meshheading:12121233-Humans,
pubmed-meshheading:12121233-Immunohistochemistry,
pubmed-meshheading:12121233-Immunophenotyping,
pubmed-meshheading:12121233-Lymphoma,
pubmed-meshheading:12121233-Male,
pubmed-meshheading:12121233-Microscopy, Electron,
pubmed-meshheading:12121233-Middle Aged,
pubmed-meshheading:12121233-Tumor Markers, Biological
|
| pubmed:year |
2002
|
| pubmed:articleTitle |
Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases.
|
| pubmed:affiliation |
Service of Pathologic Anatomy and Hematopathology, Institute of Haematology and Clinical Oncology L.e A. Seràgnoli, Bologna University, Italy. pileri@almadns.unibo.it
|
| pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|